Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 0.694 USD 2.66% Market Closed
Market Cap: 62.8m USD
Have any thoughts about
Verrica Pharmaceuticals Inc?
Write Note

Operating Margin
Verrica Pharmaceuticals Inc

-843.1%
Current
-1 639%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-843.1%
=
Operating Profit
-77.6m
/
Revenue
9.2m

Operating Margin Across Competitors

Country US
Market Cap 62.8m USD
Operating Margin
-843%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 729.3B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.6T DKK
Operating Margin
44%
Country US
Market Cap 347.8B USD
Operating Margin
28%
Country US
Market Cap 248.3B USD
Operating Margin
34%
Country CH
Market Cap 197.2B CHF
Operating Margin
32%
Country UK
Market Cap 159B GBP
Operating Margin
21%
Country CH
Market Cap 169.7B CHF
Operating Margin
31%
Country US
Market Cap 149.4B USD
Operating Margin
22%
No Stocks Found

Verrica Pharmaceuticals Inc
Glance View

Market Cap
62.8m USD
Industry
Pharmaceuticals

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

VRCA Intrinsic Value
1.338 USD
Undervaluation 48%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-843.1%
=
Operating Profit
-77.6m
/
Revenue
9.2m
What is the Operating Margin of Verrica Pharmaceuticals Inc?

Based on Verrica Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -843.1%.